Dacomitinib/Dozerun can be taken for a maximum of several years

Dacomitinib/Dacomitinib (Dacomitinib) is a new generation of oral irreversible EGFR tyrosine kinase inhibitor (EGFR-TKI), mainly used to treat patients with EGFR mutation-positive non-small cell lung cancer (NSCLC). Compared with earlier generation EGFR inhibitors, dacomitinib's irreversible inhibition of EGFR provides longer-lasting and more stable signal blockade, thereby delaying tumor progression. However, there is no fixed upper limit on the duration of its administration, and the treatment period mainly depends on the patient's tolerance to the drug, disease control, and the development of drug resistance.

In general, dacomitinib should be continued until the patient develops intolerable side effects or until the disease progresses significantly. In clinical practice, some patients may continue to take the drug for several years and still maintain stable disease, but there are also patients who adjust the dose or stop taking the drug due to drug resistance or side effects after using it for several months. Patients who tolerate it well can achieve maximum clinical benefit by maintaining treatment long-term with regular follow-up and laboratory monitoring.

Long-term use of dacomitinib requires attention to possible adverse reactions, such as rash, diarrhea, stomatitis, nail abnormalities, and abnormal liver function. Through dose adjustment, symptomatic treatment, and regular monitoring, these side effects can often be effectively managed, allowing for prolonged use. In addition, patients need to regularly review imaging and hematological indicators in order to promptly evaluate the efficacy and adjust the treatment plan.

In general, the taking time of dacomitinib is not strictly defined by the number of years, but can be flexibly adjusted based on individual treatment response and tolerance. For patients with EGFR mutation-positive non-small cell lung cancer, scientific, long-term standardized medication combined with professional follow-up is the key to obtaining the best curative effect. As research and real-world data accumulate, clearer long-term medication guidelines may emerge in the future, but currently, with efficacy and safety as the core principles, patients can take dacomitinib long-term under the guidance of doctors to achieve sustained disease control.

Reference materials:https://www.pfizer.com/products/product-detail/vizimpro